Robert J Aversa

3PUBLICATIONS
6CO-AUTHORS
Molecular targetsBiomolecular modelling and design
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|Aug 20, 2025
Discovery of Selective and Orally Bioavailable Heterobifunctional Degraders of Cyclin-Dependent Kinase 2.

Philip N Collier, Xiaozhang Zheng, Melissa Ford

|May 07, 2019
Design and Discovery of <i>N</i>-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic.

Savithri Ramurthy, Benjamin R Taft, Robert J Aversa

|May 31, 2017
Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers.

Gisele A Nishiguchi, Alice Rico, Huw Tanner

Pageof 1

Frequent Collaborators

2 joint publications

Savithri Ramurthy

1 joint publications

Philip N Collier

1 joint publications

Xiaozhang Zheng

1 joint publications

Joseph D Growney